Pasar al contenido principal

NUEVAS PROTEINAS MULTIEPITOPICAS POLIVALENTES DIRIGIDAS A ACTIVAR CELULAS B Y T COMO CANDIDATOS VACUNALES FRENTE A VIH Y SARS-COV-2

PID2020-117425RB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

  • Marcos Villar, Laura
  • Meyerhans, Andreas
  • Gómez, Carmen Elena
Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations., This investigation was supported by Preclinical development of innovative mRNA/MVA vaccines against SARS-CoV-2, COVARNA Consortium, Instituto de Salud Carlos III and Generalitat de Catalunya, La CaixaImpulse grant CF01-00008 and Ferrovial and MAPFRE donations (to ME). We also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). This study was partially supported by grants from the Spanish State Research Agency (PID2020-117425RB-C22), the Instituto de Salud Carlos III (grants: COV20/00214; ICI20/00067; FIS PI18/00699; FIS PI22/00814), the Fondo Europeo para el Desarrollo Regional (FEDER) the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653, Competitive Reference Groups, Consellería de Educación e Ordenación Universitaria, Xunta de Galicia, Ref: ED431C 2021/17 and the European Union (European Regional Development Fund - ERDF) “ REF: ED431G 2019/02”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate

  • Perdiguero, Beatriz
  • Marcos-Villar, Laura
  • López-Bravo, María
  • Sánchez-Cordón, Pedro J.
  • Zamora, Carmen
  • Valverde, José Ramón
  • Sorzano, Carlos Óscar S.
  • Sin, Laura
  • Álvarez, Enrique
  • Ramos, Manuel
  • Val, Margarita del
  • Esteban, Mariano
  • Gómez, Carmen E.
23 Pág., Introduction: While there has been considerable progress in the development of vaccines against SARS-CoV-2, largely based on the S (spike) protein of the virus, less progress has been made with vaccines delivering different viral antigens with cross-reactive potential. Methods: In an effort to develop an immunogen with the capacity to induce broad antigen presentation, we have designed a multi-patch synthetic candidate containing dominant and persistent B cell epitopes from conserved regions of SARS-CoV-2 structural proteins associated with long-term immunity, termed CoV2-BMEP. Here we describe the characterization, immunogenicity and efficacy of CoV2-BMEP using two delivery platforms: nucleic acid DNA and attenuated modified vaccinia virus Ankara (MVA). Results: In cultured cells, both vectors produced a main protein of about 37 kDa as well as heterogeneous proteins with size ranging between 25-37 kDa. In C57BL/6 mice, both homologous and heterologous prime/boost combination of vectors induced the activation of SARS-CoV-2-specific CD4 and CD8 T cell responses, with a more balanced CD8+ T cell response detected in lungs. The homologous MVA/MVA immunization regimen elicited the highest specific CD8+ T cell responses in spleen and detectable binding antibodies (bAbs) to S and N antigens of SARS-CoV-2. In SARS-CoV-2 susceptible k18-hACE2 Tg mice, two doses of MVA-CoV2-BMEP elicited S- and N-specific bAbs as well as cross-neutralizing antibodies against different variants of concern (VoC). After SARS-CoV-2 challenge, all animals in the control unvaccinated group succumbed to the infection while vaccinated animals with high titers of neutralizing antibodies were fully protected against mortality, correlating with a reduction of virus infection in the lungs and inhibition of the cytokine storm. Discussion: These findings revealed a novel immunogen with the capacity to control SARS-CoV-2 infection, using a broader antigen presentation mechanism than the approved vaccines based solely on the S antigen., This research was supported by La Caixa Banking Foundation grant CF01-00008, Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency grant PID2020-117425RB-C22, Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry and Instituto de Salud Carlos III), CSIC grant 2020E84 and Ferrovial donations (to ME). Acknowledgments, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers

  • Álvarez, Enrique
  • Falqui, Michela
  • Sin, Laura
  • McGrail, Joseph Patrick
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Marcos-Villar, Laura
  • Tárrega, Céline
  • Esteban, Mariano
  • Gómez, Carmen E.
  • Guerra, Susana
The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine., This research was supported by Spanish Ministry of Science and Innovation (MCIN)/Spanish State Research Agency, state secretary of R + D and FEDER/FSE grants: SAF2017-88089-R and PDC2021-121307-I00 to S.G. and M.E., PID2020-117425RB-C21 to S.G. and PID2020-117425RB-C22 to C.E.G., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  • Falqui, Michela
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Albert, Manuel
  • Marcos-Villar, Laura
  • McGrail, Joseph Patrick
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen Elena
  • Guerra, Susana
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., This research was supported by the Spanish State Research Agency Ministry of Health of Spain, State secretary of R+D and FEDER/FSE, SAF-2017-88089-R, PDC2021-121307-I00 PID2020- 117425RB-C21 to SG and PID2020-117425RB-C22 to CG; by CIBER consortium, Thematic Area in Infectious Diseases: CIBERINFEC (CB21/13/00108) to CG; by Red Temática de Investigación Cooperativa en Salud: Red Española de Investigación en Sida (RIS) RD16/0025/0014 and in part by European HIV Vaccine Alliance (EHVA) grant ID: 681032 to ME., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

  • Perdiguero, Beatriz
  • Pérez, Patricia
  • Marcos-Villar, Laura
  • Albericio, Guillermo
  • Astorgano, David
  • Álvarez, Enrique
  • Sin, Laura
  • Gómez, Carmen Elena
  • García-Arriaza, Juan
  • Esteban, Mariano
Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted., We thank various agencies for continuous funding support, such as Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander) and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); Red Sida RD16/0025/0002, CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME); Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grants PID2020-114481RB-I00 (to JG-A and ME) and PID2020-117425RB-C22 (to CEG); and funds from Centro de Investigacio ́n Biome ́dica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to CEG and JG-A). We have also received funding from the European Commission-Next Generation EU through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). We also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2

  • Perdiguero, Beatriz
  • Álvarez, Enrique
  • Marcos-Villar, Laura
  • Sin, Laura
  • López-Bravo, María
  • Valverde, José Ramón
  • Sorzano, Carlos Óscar S.
  • Falqui, Michela
  • Coloma, Rocío
  • Esteban, Mariano
  • Guerra, Susana
  • Gómez, Carmen E.
[Background]: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad and durable protection against emerging variants., [Methods]: To address this, here we developed two vaccine candidates, namely (i) DNA-CoV2-TMEP, expressing the multiepitopic CoV2-TMEP protein containing immunodominant and conserved T cell regions from SARS-CoV-2 structural proteins, and (ii) MVA-CoV2-B2AT, encoding a bi-cistronic multiepitopic construct that combines conserved B and T cell overlapping regions from SARS-CoV-2 structural proteins., [Results]: Both candidates were assessed in vitro and in vivo demonstrating their ability to induce robust immune responses. In C57BL/6 mice, DNA-CoV2-TMEP enhanced the recruitment of innate immune cells and stimulated SARS-CoV-2-specific polyfunctional T cells targeting multiple viral proteins. MVA-CoV2-B2AT elicited NAbs against various SARS-CoV-2 variants of concern (VoCs) and reduced viral replication and viral yields against the Beta variant in susceptible K18-hACE2 mice. The combination of MVA-CoV2-B2AT with a mutated ISG15 form as an adjuvant further increased the magnitude, breadth and polyfunctional profile of the response., [Conclusion]: These findings underscore the potential of these multiepitopic proteins when expressed from DNA or MVA vectors to provide protection against SARS-CoV-2 and its variants, supporting their further development as next-generation COVID-19 vaccines., This research was supported by La Caixa Banking Foundation, grant CF01-00008; Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency, grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100; Fondo COVID-19, grant COV20/00151 (Spanish Health Ministry and ISCIII); CSIC, grant 2020E84; and Ferrovial donations (to M.E.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2

  • García-Arriaza, Juan
  • Falqui, Michela
  • Pérez, Patricia
  • Coloma, Rocío
  • Perdiguero, Beatriz
  • Álvarez, Enrique
  • Marcos-Villar, Laura
  • Astorgano, David
  • Campaña Gómez, Irene
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen E.
  • Guerra, Susana
[Background] Vaccines represent one of the most affordable and efficient tools for controlling infectious diseases; however, the development of efficacious vaccines against complex pathogens remains a major challenge. Adjuvants play a relevant role in enhancing vaccine-induced immune responses. One such molecule is interferon-stimulated gene 15 (ISG15), a key modulator of antiviral immunity that acts both through ISGylation-dependent mechanisms and as a cytokine-like molecule., [Methods] In this study, we assessed the immunostimulatory potential of ISG15 as an adjuvant in Modified Vaccinia virus Ankara (MVA)-based vaccine candidates targeting Zika virus (ZIKV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Early innate responses and immune cell infiltration were analyzed in immunized mice by flow cytometry and cytokine profiling. To elucidate the underlying mechanism of action of ISG15, in vitro co-infection studies were performed in macrophages. Finally, we evaluated the magnitude and functional quality of the elicited antigen-specific cellular immune responses in vivo., [Results] Analysis of early innate responses revealed both platform- and variant-specific effects. ISG15AA preferentially promoted natural killer (NK) cell recruitment at the injection site, whereas ISG15GG enhanced myeloid cell infiltration in draining lymph nodes (DLNs), particularly when delivered via MVA. Moreover, in vitro co-infection of macrophages with MVA-based vaccine vectors and the ISG15AA mutant led to a marked increase in proinflammatory cytokine production, highlighting a dominant role for the extracellular, ISGylation-independent functions of ISG15 in shaping vaccine-induced immunity. Notably, co-infection of ISG15 with MVA-ZIKV and MVA-SARS-CoV-2 vaccine candidates enhanced the magnitude of antigen-specific immune responses in both vaccine models., [Conclusions] ISG15, particularly in its ISGylation-deficient form, acts as a promising immunomodulatory adjuvant for viral vaccines, enhancing both innate and adaptive immune responses. Consistent with previous findings in the context of Human Immunodeficiency virus type 1 (HIV-1) vaccines, this study further supports the potential of ISG15 as an effective adjuvant for vaccines targeting viral infections such as ZIKV and SARS-CoV-2., This research was supported by the Spanish State Research Agency SAF-2017-88089-R, PDC2021-121307-I00, and PID2020-117425RB-C21 to S.G; PID2020-117425RB-C22 to C.E.G; CSIC grant 202120E079 and grant CNS2022-135511, funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.130/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research to J.G.-A; CSIC grant 2020E84 to M.E.; Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 to J.G.-A. and M.E., and funds from the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), co-financed with FEDER funds to C.E.G and J.G.-A. This research work was also funded by the European Commission–NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E). The funders were not involved in the study design, collection, analysis, interpretation of data, writing of this article, or decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

  • Marcos-Villar, Laura
  • Perdiguero, Beatriz
  • Sin, Laura
  • Álvarez, Enrique
  • Flores, Sara
  • Casasnovas, José María
  • Pons, Tirso
  • Sorzano, Carlos Óscar S.
  • Hoyo, Daniel del
  • Lapuhs, Philipp
  • Alonso, María J.
  • Esteban, Mariano
  • Gómez, Carmen E.
Introduction: The emergence of immune-evasive SARS-CoV-2 variants has exposed limitations in the breadth and durability of protection conferred by current Spike-based vaccines, highlighting the need for next-generation approaches targeting conserved viral regions. Here, we describe the design and preclinical evaluation of an optimized multi-epitope vaccine, CoV2-BMEPu. Methods: CoV2-BMEPu was rationally designed using immunological data from SARS-CoV-2 convalescent cohorts, incorporating conserved and immunodominant regions from the Spike (S), Membrane (M) and Nucleocapsid (N) proteins, together with selected receptor-binding domain (RBD) segments associated with broadly neutralizing antibodies. The construct was engineered as a secreted trimeric antigen and delivered as an mRNA vaccine formulated in lipid nanoparticles (LNPs). In vitro expression, innate immune activation, immunogenicity and protective efficacy were evaluated in cell systems and mouse models. Results: mRNA-BMEPu was efficiently expressed in vitro as soluble oligomers and triggered innate immune activation in human macrophages. In C57BL/6 mice, LNP-BMEPu elicited robust binding and neutralizing antibodies against the ancestral virus and antigenically distant Omicron subvariants. Vaccination also induced strong and polyfunctional CD8⁺ T cell and T follicular helper responses that persisted over time. In K18-hACE2 transgenic mice, immunization conferred complete protection against lethal SARS-CoV-2 challenge, with effective control of viral replication and reduced lung inflammation. Discussion: These results support CoV2-BMEPu as a next-generation multi-epitope mRNA vaccine candidate capable of inducing broad, durable and protective immunity against current and emerging SARS-CoV-2 variants. Copyright © 2026 Marcos-Villar, Perdiguero, Sin, Álvarez, Flores, Casasnovas, Pons, Sorzano, del Hoyo, Lapuhs, Alonso, Esteban and Gómez., The author(s) declared that financial support was received for this work and/or its publication. This study was supported by multiple public and private sources. Financial support was provided by La Caixa Banking Foundation (grant CF01-00008), MICIN through the Spanish Research Agency under grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100, as well as by the COVID-19 Fund of the Spanish Health Ministry and Instituto de Salud Carlos III (grant COV20/00151) and CIBERINFEC., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

  • Marcos Villar, Laura
  • Meyerhans, Andreas
  • Gómez, Carmen Elena
Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations., This investigation was supported by Preclinical development of innovative mRNA/MVA vaccines against SARS-CoV-2, COVARNA Consortium, Instituto de Salud Carlos III and Generalitat de Catalunya, La CaixaImpulse grant CF01-00008 and Ferrovial and MAPFRE donations (to ME). We also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). This study was partially supported by grants from the Spanish State Research Agency (PID2020-117425RB-C22), the Instituto de Salud Carlos III (grants: COV20/00214; ICI20/00067; FIS PI18/00699; FIS PI22/00814), the Fondo Europeo para el Desarrollo Regional (FEDER) the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653, Competitive Reference Groups, Consellería de Educación e Ordenación Universitaria, Xunta de Galicia, Ref: ED431C 2021/17 and the European Union (European Regional Development Fund - ERDF) “ REF: ED431G 2019/02”.